Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib

J Rheumatol. 2003 Feb;30(2):421-2.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / administration & dosage*
  • Female
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Lactones / administration & dosage*
  • Male
  • Membrane Proteins
  • Middle Aged
  • Osteoarthritis / drug therapy*
  • Prostaglandin-Endoperoxide Synthases
  • Sulfones
  • Thrombosis / chemically induced*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Lactones
  • Membrane Proteins
  • Sulfones
  • rofecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases